Invention Grant
- Patent Title: FXR agonist
-
Application No.: US16628169Application Date: 2018-07-06
-
Publication No.: US11352358B2Publication Date: 2022-06-07
- Inventor: Wenkui Ken Fang , Bo Chen , Tingzhong Wang , Jing Cheng
- Applicant: XUANZHU BIOPHARMACEUTICAL CO., LTD.
- Applicant Address: CN Shijiazhuang
- Assignee: XUANZHU BIOPHARMACEUTICAL CO., LTD.
- Current Assignee: XUANZHU BIOPHARMACEUTICAL CO., LTD.
- Current Assignee Address: CN Shijiazhuang
- Agency: Ditthavong, Steiner & Mlotkowski
- Priority: CN201710547157.X 20170706
- International Application: PCT/CN2018/094813 WO 20180706
- International Announcement: WO2019/007418 WO 20190110
- Main IPC: C07D417/14
- IPC: C07D417/14 ; A61K31/428 ; C07D471/08

Abstract:
The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a compound of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer of the compound, the salt or the ester, wherein R1, X1, X2, M, Ar, ring A, ring B and L are as defined in the specification. The present invention also relates to: a preparation method for the compound, a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer of the compound, the salt or the ester; a pharmaceutical composition and pharmaceutical formulation containing the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer of the compound, the salt or the ester; and a use of the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer of the compound, the salt or the ester in the preparation of a medicament for treating and/or preventing FXR-mediated diseases.
Public/Granted literature
- US20210024522A1 FXR AGONIST Public/Granted day:2021-01-28
Information query